In this report, PricewaterhouseCoopers evaluates the effect of pharmacogenomics on the life sciences and pharmaceutical industries in the United States, highlighting the clinical impacts. This focus includes each step of the process, from clinical trial design to prescribing and monitoring treatment regimens for patients.
Our report analyzes the current blockbuster business model and traditional drug development processes, both of which are under increasing pressure. We compare the established approaches with the emerging pharmacogenomics approach.
Through case studies, the benefits of pharmacogenomics products, as well as the challenges involved in their development and market acceptance, are illustrated.
Finally, the report looks ahead to how pharmacogenomics will change the dynamics among the large pharmaceutical and smaller life sciences companies. The latter, which include biotechnology and biopharmaceutical companies, are likely to benefit most through expanded opportunities, attainable markets, and increased power in their negotiations with the pharmaceutical giants.
Despite its promise, pharmacogenomics faces significant technical and societal
challenges. This report summarizes the factors governing the speed and ease with which pharmacogenomics will reshape the pharmaceutical industry as pharmacogenomics products are expected to be a part of mainstream medical practice within 10 years.
To obtain printed copies, please contact your nearest
PwC office.
Publications Search Page
